Joanna E. Siegel

TL;DR: The Second Panel on Cost-Effectiveness in Health and Medicine reviewed the current status of the field of cost-effectiveness analysis and developed a new set of recommendations, including the recommendation to perform analyses from 2 reference case perspectives and to provide an impact inventory to clarify included consequences.

TL;DR: Four recent policy debates-involving prostate-specific antigen (PSA) screening, high-dose chemotherapy for breast cancer, antibiotic therapy for otitis media, and newborn hearing screening are used to illustrate how this approach can help clarify areas of agreement and disagreement of the opposing sides.

TL;DR: The Deliberative Methods Demonstration as discussed by the authors examined the effectiveness of public deliberation for obtaining informed public input regarding the role of medical evidence in U.S. healthcare and found that participating in deliberation increased participants' knowledge of evidence and comparative effectiveness research.

TL;DR: Key topics for future research and policy in cost-effectiveness analysis are presented, including CEA and perspectives, modeling, health outcomes, costing, evidence synthesis, and reporting and communicating CEAs.

TL;DR: The Deliberative Methods Demonstration as discussed by the authors examined the effectiveness of public deliberation for obtaining informed public input regarding the role of medical evidence in U.S. healthcare and found that participating in deliberation increased participants' knowledge of evidence and comparative effectiveness research and shifted participants' attitudes regarding the importance of evidence in decision-making.